Ironwood Pharmaceuticals (IRWD) Equity Ratio (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Equity Ratio across 17 years of filings, most recently posting 0.5 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.5, up 51.06% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.5 (up 51.06% YoY), and the FY2025 annual result was 0.66, up 23.18% from the prior year.
• Equity Ratio came in at 0.5 for Q1 2026 at Ironwood Pharmaceuticals, up from 0.66 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.61 in Q1 2023 to a low of 1.02 in Q1 2025.
• The 5-year median for Equity Ratio is 0.62 (2023), against an average of 0.32.
• Across the five-year window, Equity Ratio surged 159.95% in 2022 and sank 13246.23% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Equity Ratio stood at 0.59 in 2022, then slumped by 101.09% to 0.01 in 2023, then tumbled by 13246.23% to 0.86 in 2024, then gained by 23.18% to 0.66 in 2025, then rose by 24.26% to 0.5 in 2026.
• The last three Equity Ratio figures came in at 0.5 (Q1 2026), 0.66 (Q4 2025), and 0.67 (Q3 2025), per Business Quant data.